DDIT3 and diffuse large B-cell lymphoma: Similarly, the addition of glofitamab to R-CHOP in newly diagnosed high-risk DLBCL (defined by ctDNA dynamics) resulted in high response rates and a favorable safety profile in the phase I study [31].